project type

Leukaemia

Advanced pre-clinical evaluation of sphingosine kinase 1-targeting agents as a therapy for acute myeloid leukaemia

Developing a novel targeted therapy for treating chemotherapy-resistant leukaemia

Exploiting a new epigenetic regulatory mechanism for sustaining leukaemia-initiating activity

MARCH5 is a master regulator of BCL2 proteins and a potential anti-cancer drug target

Uncovering the biology of Chronic Myelomonocytic Leukaemia to identify prognostic and treatment opportunities

Help us to put an end to cancer